Share on LinkedInShare on LinkedIn

ARTICLE · 08 JUNE 2022

COVID-19 Vaccines: No Sharing Of Know-How

We don't get to discuss know-how much in our articles. Yet it is, of course, something that falls squarely within the domain of intellectual property law because know-how is often protected by patents.

South AfricaIntellectual Property

We don't get to discuss know-how much in our articles. Yet it is, of course, something that falls squarely within the domain of intellectual property law because know-how is often protected by patents.

The issue at hand

On 29 April 2022, the BBC published an article headed "Investors lose vote to share Covid vaccine know-how." The sub-heading fills in the gaps: "Three of the world's biggest Covid vaccine makers have seen off attempts to make them share the know-how to make their jabs."

Moderna, Pfizer and Johnson & Johnson are three of the pharmaceutical giants that make COVID-19 vaccines. Investors in these companies proposed a vaccine know-how share with companies in developing countries in order to ensure that people in the developing world also get vaccinated. In each case, the proposal was rejected. The argument advanced for a know-how share was simple: it will speed up the vaccine rollout. The argument against a know-how share was seemingly something

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

See more popular content from